Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10048730 | 0.79 | PDE4A (0.32) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6762123 | 0.78 | — | — | |
| SCHEMBL3176525 | 0.75 | SQOR (0.35) | — | |
| SCHEMBL6762127 | 0.70 | — | — | |
| SCHEMBL616113 | 0.70 | MCL1 (0.31) | — | |
| SCHEMBL6623394 | 0.68 | SLC13A5 (0.33) | — | |
| SCHEMBL10048739 | 0.67 | ALDH1A1 (0.31) | — | |
| SCHEMBL4402294 | 0.67 | AURKA (0.33) | — | |
| SCHEMBL31437498 | 0.67 | AURKA (0.33) | — | |
| SCHEMBL18556092 | 0.65 | OPRM1 (0.41) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1378505-B1 | METHOD OF SYNTHESIZING CAMPTOTHECIN-RELATING COMPOUNDS | YAKULT HONSHA KK (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-8466287-B2 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120041204-A1 | PROCESS FOR PRODUCING TRICYCLIC KETONE | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2012-02-16 | — | — | US | disclosed |
| US-8067595-B2 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067595-B2 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20090023927-A1 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023927-A1 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-01-22 | — | — | US | disclosed |
| US-7378555-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378555-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378555-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1900740-A1 | PROCESS FOR PRODUCING TRICYCLIC KETONE | Kabushiki Kaisha Yakult Honsha (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-7126000-B2 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20040106830-A1 | Method of synthesizing camptothecin-relating compounds | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2004-06-03 | — | — | US | disclosed |
| US-6723853-B2 | ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH | 2004-04-20 | — | — | US | disclosed |
| EP-1378505-A1 | METHOD OF SYNTHESIZING CAMPTOTHECIN-RELATING COMPOUNDS | Kabushiki Kaisha Yakult Honsha (JP) | 2004-01-07 | — | — | EP | disclosed |
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-17 | — | — | US | disclosed |
| WO-2003018559-A2 | INTERMEDIATES AND PREPARATION THEREOF FOR THE ENANTIOSELECTIVE SYNTHESIS OF (20R) HOMOCAMPTOTHECINS | UNIVERSITY OF PITTSBURGH (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | FOLR1, POR, FOLR2 | PDE4A 4633/4885PDE4B 4172/4885PDE4C 4292/4885 |
| US-20120041204-A1 | PROCESS FOR PRODUCING TRICYCLIC KETONE | TKT, DCK, COASY | PDE4A 1719/4885PDE4B 1413/4885PDE4C 1600/4885 |
| US-20070010674-A1 | Method of synthesizing camptothecin-relating compounds | PAICS, DHPS, TOP2A | PDE4A 806/4885PDE4B 453/4885PDE4C 735/4885 |
| US-20040106830-A1 | Method of synthesizing camptothecin-relating compounds | PAICS, DHPS, TOP2A | PDE4A 788/4885PDE4B 417/4885PDE4C 669/4885 |
| US-20090023927-A1 | Process for producing tricyclic ketone | TKT, DCK, COASY | PDE4A 1719/4885PDE4B 1413/4885PDE4C 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.